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ORIGINAL ARTICLE
Positive predictive value of ELISpot in BAL and pleural fluid from patients
with suspected pulmonary tuberculosis
Regina W. Hoflanda,b, Steven F. T. Thijsenc, Anne S. R. van Lindertb, Wiel C. M. de Langed,
Tamara van Gorkomc, Ingeborg van der Tweele, Jan-Willem J. Lammersb and Aik W. J. Bossinka
aDepartment of Respiratory Medicine, Diakonessenhuis, Utrecht, The Netherlands; bDepartment of Respiratory Medicine, University
Medical Centre Utrecht, Utrecht, The Netherlands; cDepartment of Medical Microbiology and Immunology, Diakonessenhuis, Utrecht,
The Netherlands; dDepartment of Tuberculosis, Beatrixoord Haren, University Medical Centre Groningen, Groningen, The Netherlands;
eDepartment of Biostatistics and Research Support, Julius Centre for Health Sciences and Primary Care, University Medical Centre
Utrecht, Utrecht, The Netherlands
ABSTRACT
Background: The aim of this study was to evaluate the positive predictive value (PPV) of
ELISpot in bronchoalveolar lavage (BAL) and pleural fluid for the diagnosis of active tuberculosis
(TB) in real-life clinical practice, together with the added value of a cut-off >1.0 for the ratio
between the extra-sanguineous and systemic interferon-gamma responses in positive samples.
Methods: A retrospective, single-centre study was performed. Patients with positive ELISpot in
BAL and pleural fluid were included.
Results: The PPV for TB in patients with positive ELISpot in BAL (n¼ 40) was 64.9%, which
increased to 82.6% for the ESAT-6 panel and 71.4% for the CFP-10 panel after the introduction
of a cut-off >1.0 for the ratio between the BAL and blood interferon-gamma responses. In
patients with positive ELISpot in pleural fluid (n¼ 16), the PPV for TB was 85.7%, which increased
to 91.7% for the ESAT-6 panel and 92.3% for the CFP-10 panel after the introduction of a cut-off
>1.0 for the ratio between the pleural fluid and blood interferon-gamma responses.
Conclusions: This report describes the PPV of ELISpot in BAL and pleural fluid for the diagnosis
of active TB in real-life clinical practice. The results indicate the possibility of an increase of the
PPV using a cut-off >1.0 for the ratio between the extra-sanguineous and systemic interferon-
gamma responses. Further studies are needed to underline this ratio-approach and to evaluate
the full diagnostic accuracy of ELISpot in extra-sanguineous fluids like BAL and pleural fluid.
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Tuberculosis (TB) results in high morbidity and mor-
tality worldwide, and rapid diagnosis is still a major
challenge. In the Netherlands, 25% of patients are
treated for TB without a definitive diagnosis due to
negative acid-fast staining, polymerase chain reac-
tion (PCR) and culture, indicating the need for add-
itional diagnostic tools.
In recent years, Mycobacterium tuberculosis (MTB)-
specific interferon-gamma release assays (IGRA) in
extra-sanguineous fluids have been investigated for
use in the diagnosis of TB, based on the theory that
MTB-specific T-lymphocytes are concentrated at the
site of infection due to homing and antigen-specific
proliferation.[1] A systematic review summarized the
current evidence about the diagnostic accuracy of
these tests.[2] Concerning T-SPOT.TB (Enzyme-Linked
ImmunoSpot assay, ELISpot) in extra-sanguineous
fluids, the pooled sensitivity and specificity were 88%
and 82%, respectively. For Quantiferon Gold-in tube
in extra-sanguineous fluids, this was 48% and 82%,
respectively. Another systematic review about the
diagnostic performance of MTB-specific IGRA in pleu-
ral fluid combined the results of ELISpot and
Quantiferon Gold-in tube, resulting in the pooled
sensitivity and specificity of 72% and 78%, respect-
ively.[3,4] The results of both reviews indicate the
diagnostic superiority of ELISpot compared with
Quantiferon Gold-in tube in extra-sanguineous fluids;
however, the clinical utility of IGRA in extra-sanguin-
eous fluids is still under research. Especially, the
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limited positive predictive value (PPV), although not
evaluated in both reviews, seems a limitation of this
test as in a large, multicentre study in a low TB-
endemic area, the PPV of MTB-specific IGRA in bron-
choalveolar lavage (BAL) was only 55%.[5]
In active TB, frequencies of interferon-gamma
producing MTB-specific T-lymphocytes concentrated
at the site of infection are shown to be higher com-
pared with frequencies of interferon-gamma pro-
ducing MTB-specific T-lymphocytes in peripheral
blood,[1,5,6] probably resulting in a ratio of >1.0
between the extra-sanguineous and systemic inter-
feron-gamma responses. The introduction of a cut-
off ratio >1.0 between the extra-sanguineous and
systemic interferon-gamma responses could theoret-
ically increase the PPV of IGRA in extra-sanguineous
fluids. This item is not addressed in either review
[2,3]; however, a cut-off has been suggested by
some reports.[1,7–9] These studies included limited
number of subjects and, moreover, three of these
studies [7–9] were from a high TB-endemic area,
making it difficult to extrapolate the results to lower
endemic areas.
In our hospital, the application of MTB-specific
IGRA (ELISpot) in extra-sanguineous fluids is part of
the diagnostic evaluation in patients with a clinical
suspicion of active TB. The aim of this study was to
evaluate the PPV of ELISpot in BAL and pleural fluid
for the diagnosis of active TB in real-life clinical
practice, together with the added value of a cut-off
>1.0 for the ratio between the extra-sanguineous




A retrospective, single-centre study was performed
in a hospital in Utrecht, The Netherlands. All
patients with positive ELISpot in BAL and pleural
fluid from 2006 to 2012 of whom concurrent
ELISpot blood results were available (in order to
allow the ratio-analysis between the extra-sanguin-
eous and systemic interferon-gamma responses)
were included, with a follow-up of at least two
years. Patients with negative or indeterminate
ELISpot in BAL and pleural fluid were excluded.
Patient characteristics, including age, gender,
comorbidities, medication, smoking habits, country
of origin, travel history, BCG vaccination status,
tuberculin skin test (TST) results, Human immuno-
deficiency virus (HIV) status, clinical signs and symp-
toms, laboratory results, thoracic imaging results,
microbiological results and blood ELISpot-assay
results were examined from medical records.
Diagnostic work-up
In TB suspect patients, the regular work-up
consisted of blood examination for ELISpot TB and
inflammatory markers (including leucocyte count
and C-reactive protein levels) together with thoracic
imaging (X-ray or computed tomography (CT)-scan).
In all patients suspected of having pulmonary TB but
who were unable to cough up sputum or with three
samples smear-negative sputum (not special morn-
ing sputum), BAL was performed with 150mL saline
fluid placed into an affected lung segment. Gastric
lavages were not used. In patients suspected of
tuberculous pleuritis, 20mL pleural fluid was col-
lected, of which 10mL was used for PCR and culture.
Diagnostic tests performed at BAL and pleural fluid
included always MTB-specific IGRA (ELISpot), acid-
fast staining using auramine, PCR for MTB, standard
culture for bacterial pathogens and mycobacterial
culture. For PCR technique, prior to DNA extraction,
samples underwent a pre-extraction preparation
method using a combination of N-acetyl-L-cysteine
and sodium hydroxide (NALC–NaOH).[10] DNA was
isolated using Magnapure LC (Roche, Almere, the
Netherlands) according to the manufacturer’s
instructions. The MTB-specific PCR was performed
using primer set 2 targeted on the IS6110 sequence.
PCR was performed using the ABI Prism 75,000
sequence detection system (Applied Biosystems,
Foster City, CA).[11] For mycobacterial culture, speci-
mens were inoculated using a MGIT system (Becton
Dickinson, Shannon, Ireland). Positive cultures were
verified using acid-fast staining and PCR for MTB.
Positive cultures were subsequently referred to the
National Institute for Public Health and the
Environment for identification and antimicrobial sus-
ceptibility testing.
Interferon-gamma release assay
MTB-specific IGRA (ELISpot) in peripheral blood
mononuclear cells (PBMCs) was performed using
348 R. W. HOFLAND ET AL.
the T-SPOT.TB platform, according to the man-
ufacturer’s instructions (Oxford Immunotec Ltd.,
Abingdon, UK). Briefly, 2.5 105 fresh PBMCs were
incubated with 50 lL of AIM-V medium (negative
control), phytohemagglutinin (PHA, positive control)
and two MTB-specific antigens (ESAT-6/panel A, and
CFP-10/panel B, respectively). After 16–20 h of incu-
bation at 37 C and 5% CO2, the microtitre plates
were washed and a conjugate incubation followed
by a detection step was carried out to visualize the
interferon-gamma production by sensitized T-cells.
Spot forming cells (SFCs) were enumerated using
the ELISpot reader (Auto Immun Diagnostika GmbH,
Strassberg, Germany). Definition of the results (posi-
tive, negative or indeterminate) was according to
the manufacturer’s instructions and as described
previously.[5,12] Borderline zones were not used.
ELISpot in BAL and pleural fluid was performed
as described previously.[5] Time from sampling to
start analysis was within three hours. Fresh cells
were isolated from BAL and pleural fluid, and if pos-
sible, 2.5 105 fresh cells were incubated and proc-
essed according to the protocol described above. In
the absence of validated cut-off values for ELISpot
in BAL and pleural fluid, positive, negative and inde-
terminate results were defined in agreement with
ELISpot in blood.
Tuberculosis case definition
According to the WHO guidelines,[13] the definition
of TB cases resulted in four possible diagnoses: def-
inite, probable, uncertain or no active TB. Definite
TB was diagnosed in patients with clinical findings
compatible with TB, confirmed with positive culture
and/or PCR. Patients with signs and symptoms of
TB without laboratory confirmation (negative PCR
and culture) but who recovered after treatment
with tuberculostatic drugs were defined as probable
TB. Patients with definite TB as well as patients with
probable TB are regarded to be patients with active
TB in real-life clinical practice. Patients lost to fol-
low-up and patients with an unclear clinical course
in whom no laboratory confirmation of active TB
could be obtained were classified as uncertain TB.
Finally, in cases with another diagnosis, the case
was defined as no active TB, including patients with
only latent TB infection (LTBI), defined as patients
with positive ELISpot in blood, but without
arguments for active disease. Development of active
TB was assessed with respect to at least two years
of follow-up. TB case definition was made with the
consensus of three of the authors (A.W.J.B., A.S.R.v.L.
and R.W.H.), in collaboration with an independent
TB expert who was not aware of the inclusion crite-
ria of this study (W.C.M.d.L.). This TB expert eval-
uated all cases retrospectively, with access to all
anonymized data except results of ELISpot in BAL
and pleural fluid, ensuring an independent TB case
definition.
Analysis
Baseline clinical characteristics were described as
medians and ranges in non-normally distributed
variables and percentages for categorical variables.
The PPV of ELISpot without ratio was calculated
for positive BAL and pleural fluid samples separ-
ately, dividing the number of patients with active
(definite and probable) TB by the total number of
patients with positive ELISpot in BAL respectively
pleural fluid.
The ratio between the extra-sanguineous and sys-
temic interferon-gamma responses (hereinafter
referred to as ‘ratio’) was calculated dividing the
number of SFCs in BAL respectively pleural fluid by
the number of SFCs in blood, for ESAT-6 and CFP-
10 panels separately, because of the differences in
SFCs between ESAT-6 and CFP-10 panels.
The PPV using a cut-off >1.0 for the ratio was
calculated for the ESAT-6 panel and the CFP-10
panel separately, dividing the number of patients
with active TB and ratio >1.0 by the total number
of patients with positive ELISpot in BAL respectively
pleural fluid and ratio >1.0.
Furthermore, the PPV using a cut-off >1.0 was
calculated in case of ratio>1.0 in at least one of the
two panels (either ESAT-6 or CFP-10), dividing the
number of patients with active TB and ratio >1.0 in
at least one of the two panels by the total number
of patients with positive ELISpot in BAL respectively
pleural fluid and ratio >1.0 in at least one of the
two panels.
Finally, the PPV using a cut-off >1.0 was calcu-
lated in case of ratio >1.0 in the ESAT-6 and CFP-10
panel simultaneously, dividing the number of
patients with active TB and ratio >1.0 in both pan-
els simultaneously by the total number of patients
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with positive ELISpot in BAL respectively pleural
fluid and ratio >1.0 in both panels simultaneously.
In evaluation of the PPV (with and without ratio),
patients with uncertain TB were excluded, as most
of them were lost to follow-up and definite case
definition was not possible.
Because of the limited sample size, evaluation of
the statistical significance of the added value of a
cut-off ratio>1.0 at PPV is not suitable in this study.
This study is aimed as a hypothesis generating
report and should be followed by a well-powered
prospective study.
Data were analysed using SPSS statistics version
21.0 (Armonk, NY). Figures were composed with the
aid of GraphPad Prism 6.0 (La Jolla, CA).
Results
Patients, case definition and diagnostic results
All eighty-one patients with positive ELISpot in BAL
and pleural fluid from 2006 to 2012 were evaluated.
Twenty-five patients with positive ELISpot in BAL or
pleural fluid could not be enrolled, because of the
absence of concurrent blood ELISpot blood results.
Fifty-six patients with positive ELISpot in BAL or
pleural fluid were included, of which three were lost
to follow-up. Thirty-eight patients were male.
Median age was 48 years. Of all patients, 35 were
born in a TB-endemic area (defined as countries
with an annual TB incidence of >50/100,000),[13]
and most of them are likely to be BCG-vaccinated,
although the BCG-vaccination details were not
recorded in most of the medical files. Five patients
had TB in their history. None of the patients were
HIV-positive and only two patients were using
immunosuppressive medication (one patient was
treated with 5mg prednisone daily; another patient
was treated with a combination of 15mg prednis-
one daily and methotrexate). None of the patients
not receiving treatment developed TB during fol-
low-up. The patients’ baseline characteristics are
summarized in Table 1.
Forty patients had positive ELISpot in BAL.
Sixteen patients (separate cases) had positive
ELISpot in pleural fluid as shown in Table 2. After
assessment of the cases together with the inde-
pendent TB expert, twenty-three patients (41.1%)
were classified with definite TB, (including six
patients with definite tuberculous pleuritis). Thirteen
patients (23.2%) were classified with probable TB
(including six patients with probable tuberculous
pleuritis). Five patients (8.9%) were classified with
uncertain TB, of whom three were lost to follow-up.
Another fifteen patients (26.8%) were classified with
no signs of active TB, although most of them
(n¼ 11) had LTBI because of positive ELISpot in
blood, Tables 2 and 3.
Other diagnostic results (including auramine, PCR
and culture for MTB and ELISpot in blood) are sum-
marized in Table 3, with respect to the TB case def-
inition. In only one patient, resistance to isoniazid
was established; all other MTB strains showed sensi-
tivity to all tuberculostatic drugs tested.
Positive predictive value of ELISpot in BAL and
pleural fluid and the added value of a cut-off
>1.0 for the ratio between the extra-sanguineous
and systemic interferon-gamma responses
The PPV of ELISpot in BAL fluid for active TB was
64.9% (¼24/37), Table 2. The PPV of ELISpot in pleu-
ral fluid for active TB was 85.7% (¼12/14), Table 2.
Table 1. Patients’ baseline characteristics.
Totala Observationsb
Number of subjects 56
Male 38 (67.9%) n¼ 56
Age 48 [18;84] n¼ 56
TB endemic ethnicityc 35 (63.6%) n¼ 55
TB in history 5 (9.3%) n¼ 54
Recent travelling to TB-endemic country 22 (59.5%) n¼ 37
HIV positivity 0 (0.0%) n¼ 32
Immunosuppressive medicationd 2 (3.6%) n¼ 56
aData are presented as n (%) or median [range].
bNumber of patients in which the variable is known because of missing
information in some cases.
cDefined as countries with an annual TB incidence of >50/100,000.[13]
dOne patient was treated with 5mg prednisone daily. Another patient
was treated with a combination of 15mg prednisone daily and
methotrexate.
HIV: human immunodeficiency virus; TB: tuberculosis.







No TB (n¼ 15),
including LTBI
(n¼ 11)
Positive ELISpot in BAL (n¼ 40) 17 7 3 13
Positive ELISpot in pleural fluid (n¼ 16) 6 6 2 2
BAL: bronchoalveolar lavage; TB: tuberculosis.
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The calculated ratios between the extra-sanguin-
eous and systemic interferon-gamma responses var-
ied from 0.1 to almost 300 and are represented in
Figure 1(a) (ESAT 6-panel) and Figure 1(b) (CFP-10
panel), for BAL and pleural fluid in separate colors.
In patients with no active TB, patients with and
without LTBI were represented separately.
For positive ELISpot in BAL, a ratio of >1.0
resulted in a PPV for active TB of 82.6% (¼19/23)
for the ESAT-6 panel (Figures 1(a) and 2(a)) and
71.4% (¼15/21) for the CFP-10 panel (Figures 1(b)
and 2(a)). A ratio of >1.0 in at least one of the two
panels (either ESAT-6 or CFP-10) resulted in a PPV
for active TB of 73.1% (¼19/26). A ratio of >1.0 in
the ESAT-6 and CFP-10 panel simultaneously
resulted in a PPV of 83.3% (¼15/18), Figure 2(a).
For positive ELISpot in pleural fluid, a ratio
of>1.0 resulted in a PPV for active TB of 91.7%
(¼11/12) for the ESAT-6 panel (Figures 1(a) and
2(b)) and 92.3% (¼12/13) for the CFP-10 panel
(Figures 1(b) and 2(b)). A ratio of >1.0 in at least
one of the two panels (either ESAT-6 or CFP-10)
resulted in a PPV for active TB of 92.3% (¼12/13). A
ratio of >1.0 in the ESAT-6 and CFP-10 panel simul-
taneously resulted in a PPV of 91.7% (¼11/12),
Figure 2(b).
Discussion
This retrospective study evaluates the PPV of
ELISpot in BAL and pleural fluid for the diagnosis of
Table 3. Results of ELISpot in blood; results of auramine, PCR











Positive 23 12 3 11
Negative 0 1 2 4
Auramine
Positive 5 0 0 1
Negative 18 13 5 14
PCR for MTB
Positive 13 0 0 0
Negative 10 13 5 14a
Culture for MTB
Positive 21 0 0 0
Negative 2 13 5 15
aOne missing PCR result.
MTB: Mycobacterium tuberculosis; PCR: polymerase chain reaction; TB:
tuberculosis.
Figure 1. Ratio between SFCs in BAL (black dots) respectively pleural fluid (red dots) and SFCs in blood (y-axis, scale log 10), with
respect to the tuberculosis (TB) case definition (x-axis). Results of ESAT-6 (a) and CFP-10 (b) are shown separately. In patients with
no active TB, patients with LTBI (filled dots) and without LTBI (open dots) were represented separately.
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active TB in real-life clinical practice. The results
indicate the possibility of an increase of the PPV
using a cut-off >1.0 for the ratio between the
extra-sanguineous and systemic interferon-gamma
responses. Because of the limited sample size, the
data are not appropriate for statistical tests. As a
result, recommendations about the most appropri-
ate panel (ESAT-6, CFP-10 or a combination of
both panels) for ratio-approach cannot be deter-
mined thus far. Nevertheless, the results are note-
worthy and contain important lessons for future
studies on the value of ELISpot in extra-sanguin-
eous fluids.
In theory, a positive ELISpot in BAL or pleural
fluid together with a ratio>1.0 between extra-san-
guineous and systemic interferon-gamma responses
could be helpful in the decision to initiate anti-TB
treatment in patients with negative PCR MTB
results and pending or negative culture results, but
this hypothesis needs further, carefully designed,
prospective studies to determine the definite diag-
nostic accuracy and the impact on treatment
Figure 2. PPV of ELISpot in BAL fluid (a) and pleural fluid (b) (first column) together with the added value of cut-off >1.0 for the
ratio between the extra-sanguineous and systemic interferon-gamma responses in the CFP-10 panel (second column), in the ESAT-
6 panel (third column), in at least one of the two panels (fourth column) and in the ESAT-6 and CFP-10 panel simultaneously (fifth
column).
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decision. In this study, it was not possible to evalu-
ate the impact of ELISpot results at treatment
decision.
Furthermore, this approach could prove to be
valuable in the diagnosis of extrapulmonary difficult-
to-diagnose TB (e.g. TB-meningitis),[14] although this
is difficult to study in lower endemic areas because
of the low prevalence of TB-meningitis.
This approach is not intended to replace PCR
and/or culture diagnostics, which remain essential
in identifying the TB-strain and in susceptibility test-
ing. Independently of the positioning of the value
of ELISpot in extra-sanguineous fluids, it remains
very important to improve PCR-technique (which is
an ongoing process in recent years) and to strive
for better (sputum) samples, including induced spu-
tum, all aimed to improve rapid TB-diagnosis.
An important requirement for ELISpot in BAL and
pleural fluid is the access to bronchoscopy and
ELISpot procedure, which might be a limitation in
lower income countries, but usually is not a prob-
lem in more developed countries.
As far as we know, this study is the first to expli-
citly address the PPV of ELISpot in BAL and pleural
fluid together with the added value of a cut-off >1.0
for the ratio between the extra-sanguineous and sys-
temic interferon-gamma responses in positive sam-
ples. Another strength of this study is the TB case
definition according to the WHO guidelines together
with the input of an external, blinded expert.
This study has several limitations, partially due to
the retrospective and single-centre character of the
study, which influences the possibilities to general-
ize the results.
Another limitation refers to the selection strategy.
In clinical practice, in patients with pulmonary TB
diagnosed with positive sputum samples, usually
bronchoscopy is not performed and as a conse-
quence ELISpot BAL cannot be obtained. As a result,
these patients were not included in the study.
Furthermore, as a result of the inclusion of only posi-
tive ELISpot in BAL and pleural fluid, full diagnostic
accuracy of the test including the negative predictive
value, sensitivity and specificity could not be eval-
uated. As preceding prospective studies addressed
this issue already,[2,3] and we especially aimed to
investigate the added value of the ratio-approach for
the PPV, evaluation of full diagnostic accuracy was
not the intention of this retrospective study.
Results may be influenced by the disease preva-
lence in the included population. Although the study
was performed in a low incidence country, several
patients were at a higher risk of TB because of ethni-
city or as a result of travelling to endemic areas.
Due to the low incidence of tuberculosis, this
study included relatively few patients during a lon-
ger period of time where changes in staff and diag-
nostic facilities might have affected the results.
Another reason for the limited sample size is the
exclusion of patients without concurrent ELISpot
blood results.
The exclusion of patients with uncertain TB in the
evaluation of the PPV may have affected the results
as well, although the influence of only five patients
probably is not substantial. Because of the absence
of a definite diagnosis in these five patients, the
effect of the exclusions at the results is unclear.
The lower PPV of ELISpot in BAL compared with
PPV of ELISpot in pleural fluid could be explained
by the differences in the type of fluid. BAL fluid is
the result of lavage of a lung segment, resulting in
dilution of the sputum. Furthermore, the collection
of BAL fluid results in a higher risk of blood mixture
because of possible irritation of the endobronchial
mucosa during the procedure.
Consequently, the ratio-approach is expected to
increase the PPV of ELISpot especially in BAL, as is
indicated in our results. As a consequence of the
inherent differences in yield during the collection of
BAL fluid, it is difficult to standardize the ELISpot
procedure in BAL fluids. In three patients, less than
2.5 105 cells could be harvested and incubated for
ELISpot procedure. None of these patients did have
active TB. Although this is a limitation of the study,
it is unlikely that the results of these three patients
have significantly influenced the results.
The PPV of ELISpot in BAL fluid in this study
(64.9%) is somewhat higher compared with PPV of
ELISpot in BAL fluid (55%) in previous mentioned
prospective multi-centre study,[5] possibly influ-
enced by differences in TB-endemic ethnicity of the
included patients, although this information is lack-
ing in the mentioned paper.[5] An influence of the
differences in selection strategy between both stud-
ies cannot be excluded. Both studies emphasizes
that PPV without ratio between extra-sanguineous
and systemic interferon-gamma responses is a limi-
tation of ELISpot in BAL.
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Although promising, this ‘ratio-approach’ did not
distinguish active from latent TB in all patients,
which remains a limitation of the test. Five
patients with positive ELISpot in BAL fluid and
ratio 1.0 in ESAT-6 and CFP-10 panels simultan-
eously did have active TB. Three of these patients
had mainly extrapulmonary TB with only minor
pulmonary abnormalities, necessitating caution
when interpreting BAL results in patients with
mainly extrapulmonary TB. The two other patients
with a ratio 1.0 in ESAT-6 and CFP-10 panels sim-
ultaneously definitely had pulmonary TB, one with
a positive culture for M. bovis and the other with
a positive culture for MTB. In contrast, five patients
with positive ELISpot in BAL or pleural fluid and
ratios of >1.0 in ESAT-6 and CFP-10 panels simul-
taneously did not have active TB. Three of these
patients had negative ELISpot in their blood and
just slightly positive ELISpot in BAL fluid. One
patient also had a negative ELISpot in her blood,
but with a convincingly positive ELISpot in BAL
fluid and 191 spots in ESAT-6 and CFP-10 panels
simultaneously, without arguments for active TB.
She frequently travelled to a TB-endemic area, so
the influence of possible TB exposure and subse-
quent immune activation in this ‘false-positive’
ELISpot in BAL and consequently ‘false-negative’
ELISpot in blood could be considered. One patient
had ratio of >1.0 in the ESAT-6 and CFP-10 panels
simultaneously, with positive ELISpot in blood
and pleural fluid, although without evidence of
active TB.
Evaluating the PPV of ELISpot in BAL and pleural
fluid, it is instructive to be aware of patients with
negative ELISpot in BAL or pleural fluid yet with
active TB. Therefore, we evaluated all patients
treated for TB in our hospital from 2006 until 2012.
This resulted in the identification of one patient
with definite TB in mediastinal lymph nodes (nega-
tive Auramine and PCR for MTB, but positive cul-
ture), without abnormalities in lung parenchyma
and consequently negative ELISpot BAL.
In conclusion, this report describes the PPV of
ELISpot in BAL and pleural fluid for the diagnosis of
TB. The results indicate the possibility of an increase
of the PPV using a cut-off >1.0 for the ratio
between the extra-sanguineous and systemic inter-
feron-gamma responses. Further studies are needed
to underline this ratio-approach and to evaluate full
diagnostic accuracy of ELISpot in extra-sanguineous
fluids like BAL and pleural fluid, as well as the
impact of the results on treatment decision.
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